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ABSTRACT
Constitutional mismatch repair deficiency (CMMRD)
syndrome is a distinct childhood cancer predisposition
syndrome that results from biallelic germline mutations in
one of the four MMR genes, MLH1, MSH2, MSH6 or
PMS2. The tumour spectrum is very broad, including
mainly haematological, brain and intestinal tract
tumours. Patients show a variety of non-malignant
features that are indicative of CMMRD. However,
currently no criteria that should entail diagnostic
evaluation of CMMRD exist. We present a three-point
scoring system for the suspected diagnosis CMMRD in a
paediatric/young adult cancer patient. Tumours highly
specific for CMMRD syndrome are assigned three points,
malignancies overrepresented in CMMRD two points and
all other malignancies one point. According to their
specificity for CMMRD and their frequency in the general
population, additional features are weighted with 1–2
points. They include multiple hyperpigmented and
hypopigmented skin areas, brain malformations,
pilomatricomas, a second childhood malignancy, a Lynch
syndrome (LS)-associated tumour in a relative and
parental consanguinity. According to the scoring system,
CMMRD should be suspected in any cancer patient who
reaches a minimum of three points by adding the points
of the malignancy and the additional features. The
diagnostic steps to confirm or refute the suspected
diagnosis are outlined. We expect that application of the
suggested strategy for CMMRD diagnosis will increase
the number of patients being identified at the time when
they develop their first tumour. This will allow
adjustment of the treatment modalities, offering
surveillance strategies for second malignancies and
appropriate counselling of the entire family.
INTRODUCTION
The contribution of defective mismatch repair
(MMR) to the cancer development has been
acknowledged now for over two decades (for
review, see ref. 1). Heterozygous (monoallelic)
germline mutations in the MMR genes MLH1,
MSH2, MSH6 and PMS2 cause the autosomal-
dominant Lynch syndrome (LS),2 which predis-
poses primarily to colorectal and endometrial
cancers but also to cancers of other organs, includ-
ing the small bowel, urinary tract, stomach, ovaries
and brain.3 4 Usually, affected individuals develop
cancer not before the fourth decade of life. In
LS-associated tumours, MMR deficiency and, con-
sequently, loss of repair mechanisms that protect
the genome from DNA damage result from the loss
of the wild-type MMR allele through somatic point
mutations or loss-of-heterozygosity.
In 1999, two reports described the phenotype of
the offspring from consanguineous marriages
within LS families who carried homozygous MLH1
germline mutations.5 6 These individuals developed
haematological malignancies (and one individual a
medulloblastoma) in early childhood (age range
14 months to 6 years). Of note, they also displayed
clinical features reminiscent of neurofibromatosis
type 1 (NF1). Since then, more than a hundred
paediatric and young adult cancer patients have
been reported carrying biallelic (homozygous or
compound heterozygous) germline mutations in
one of the four MMR genes involved in LS. This
recessively inherited condition is now recognised as
a distinct childhood cancer predisposition syn-
drome (OMIM #276300). The syndrome is known
by different names, among which we consider con-
stitutional MMR deficiency (CMMRD) syndrome7 8
the most appropriate one since it refers to the
underlying defect. Although molecularly not
proven, it is retrospectively most likely that Jacques
Turcot in 1959 described the first cases of
CMMRD when he reported on two siblings with
numerous colorectal adenomatous polyps, colorec-
tal carcinoma and malignant brain tumours.9
However, during the following years, patients who
should retrospectively be considered CMMRD
patients and familial adenomatous polyposis (FAP)
patients with brain tumours were lumped together
under the term Turcot syndrome.10 Hence,
CMMRD and Turcot syndrome essentially overlap.
Due to the constitutional defect in MMR cap-
acity, individuals with biallelic MMR gene muta-
tions have a high risk of developing a diverse
spectrum of malignancies already in childhood and
adolescence. The spectrum includes mainly (i)
haematological malignancies, (ii) brain/central
nervous system (CNS) tumours and (iii) colorectal
and other cancers that are typically seen in LS
patients at a later age. A variety of other malignan-
cies were seen only in a few or individual
CMMRD patients. Many of the CMMRD patients,
but not all, showed features reminiscent of NF1,
particularly multiple café au lait maculae (CALM).
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In addition or alternatively to NF1 features, other non-
neoplastic features may be present that are indicative of
CMMRD in a paediatric cancer patient. But so far no single
clinical criteria diagnostic of CMMRD emerged.
Diagnosis of CMMRD in a paediatric or young adult cancer
patient has important implications for the management not only
of the patient but also of the entire family. However, diagnosis
may often be delayed or even not stated despite the fact that
CMMRD is now defined as a distinct cancer predisposition syn-
drome with more than 60 reports on CMMRD patients already
published. The lack of awareness for this rare cancer predispos-
ition syndrome among paediatric haematologists/oncologists
may be at least partially due to diagnostic difficulties that result
from the lack of clearly disease-specific clinical features in com-
bination with the broad tumour spectrum of CMMRD. A newly
established European consortium ‘Care for CMMRD’
(C4CMMRD) addressed this issue at a workshop held at
Saint-Antoine Hospital in Paris on 9 June 2013. The outcome
of the discussion held at the workshop and thereafter with add-
itional experts in the field who were not attending the meeting
is presented here. Based on the current knowledge on the
tumour spectrum and the spectrum of non-neoplastic features,
we propose a three-point scoring system for clinical criteria that
should raise a high index of suspicion for CMMRD when
present in a paediatric/young adult cancer patient and, there-
fore, should entail diagnostic evaluation. The diagnostic steps
that should confirm or refute the suspected diagnosis are
outlined.
THE CLINICAL PHENOTYPE OF CMMRD AS DEDUCED
FROM THE KNOWN CASES
Collection of the data from the known CMMRD cases
In 2008, all 78 CMMRD patients known at that time were com-
piled in a table.8 Since then, all subsequently published patients
with a molecularly confirmed diagnosis of CMMRD were
added to this list. Retrospectively, two patients were excluded
from the original list because they carried MLH1 variants with
arguable pathogenicity, that is, NM_0002439.3:p.Ala441Thr11
and p.Lys618Ala.12 As of June 2013, the table lists 127 patients
from 79 families published in 63 papers (see online supplemen-
tary Table S1) as well as 19 so far unpublished patients (12 fam-
ilies). Of these 146 patients, 58% (60% of the families) carried
biallelic PMS2 mutations while the remaining roughly 40% of
patients/families are more or less equally distributed among
MSH6 and MLH1/MSH2 biallelics (see table 1). This distribu-
tion is in contrast to LS patients of whom the large majority
carry heterozygous MLH1 or MSH2 mutations and only a
minority heterozygous PMS2 mutations. In part, this difference
may reflect the reduced penetrance of heterozygous PMS2 muta-
tions. Studies in unselected cohorts of colorectal cancer patient
show that the prevalence of PMS2-associated LS is higher than
previously thought.13 14
In the following, we will describe the clinical phenotype as it
can be deduced from these 146 patients. Data of the so far
unpublished patients are also included in the overall analysis
presented here, but detailed information on these patients will
be published elsewhere. Since nearly all of the patients are
described as individual medical case reports, potential selection
bias must be kept in mind. To assess the full cancer spectrum
and true cancer risk associated with CMMRD natural history,
further studies that screen for CMMRD in unselected patients’
cohorts are needed. These studies will also uncover the full
spectrum and the frequency of non-neoplastic CMMRD
features.
Malignancies in CMMRD patients
In almost all (145/146) of the patients reported so far, malig-
nancies or at least premalignancies, that is, mainly bowel aden-
omas, were reported. Three biallelic mutation carriers who were
reported in the original papers to have no tumours15–17 devel-
oped malignancies under surveillance18 (Gerdes and Illencikova
2013, unreported data). Although these observations suggest an
extraordinary high tumour risk in CMMRD patients, data from
a larger number of presymptomatically tested patients followed
over a longer period of time are needed to assess the penetrance
of CMMRD with respect to cancer development.
Premalignancies and benign neoplasms not taken into account,
139 patients developed a total of 223 malignancies. In this cal-
culation, multiple synchronous colon carcinomas were counted
as only one malignancy. Table 2 summarises the spectrum and
age of diagnosis of these malignancies. Online supplementary
table S2 renders more details by splitting the data according to
the mutated MMR gene.
In more detail, 48 malignancies of the haematopoietic system
were diagnosed in 45 patients. Three patients had two different
metachronous malignancies of the haematopoietic system.
Within this group, non-Hodgkin’s lymphomas (NHL) were the
most prevalent tumour entity. Of the 31 NHL, 20 were derived
from the T-cell linage and 4 from B-cell lineage while lineage
determination was not available for the remaining. Among the
nine acute lymphoblastic leukaemias, four were classified as
T-cell acute lymphoblastic leukaemia (T-ALL) while the rest
were unclassified ALL. Acute myeloid leukaemia (AML) (five
patients) was less common. Classification was difficult in three
cases with haematological malignancies reported as atypical
chronic myeloid leukaemia, malignant lymphoma and acute
leukaemia.
Taken together, a total of 81 brain/CNS tumours were identi-
fied in 78 CMMRD patients. Among this tumour entity, the
largest group were the high-grade gliomas (58 tumours), includ-
ing 34 glioblastomas (this also includes two gliomatoses
cerebri), 8 anaplastic astrocytomas, 6 oligodendrogliomas and 2
gliosarcomas. Assuming that they were of or eventually devel-
oped into high grade, also four unspecified gliomas, three
unspecified astrocytomas and one fibrillary astrocytoma WHO
II were included in the group of high-grade gliomas. Less
common were intracranial embryonal tumours. CNS primitive
neuroectodermal tumours (CNS-PNET) developed in eight
patients and medulloblastoma in seven patients. Further, there
are individual cases with specific brain tumour entities that do
not fall into the two main categories (see table 2 and see online
supplementary Table S2) and five unspecified brain tumours
reported.




















32 (19) 7.5 0.4–39 22
MSH6 29 (17) 8 2–31 34
PMS2 85 (55) 10 1–28 42
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A total of 88 LS-associated malignancies developed in 59
patients. The vast majority were colorectal cancers (CRC). Six
patients developed metachronous CRC and at least 16 patients
presented with synchronous CRC. Because the exact number of
synchronous carcinomas was not always given, we counted mul-
tiple synchronous CRC as only one malignancy, but the meta-
chronous carcinomas each individually. Calculating by this way,
a total of 59 CRC were found in 53 patients (table 2 and online
supplementary table S2). Other LS-associated tumours were less
frequent. A total of 12 patients developed 18 independent meta-
chronous cancers of the small bowel (duodenum, jejunum,
ileum), 6 patients endometrium cancer, 4 cancer of the urethral
tract and 1 an ovarian cancer.
As can be deduced from table 2, the distribution of age at
diagnosis was broad in each of the three main tumour groups.
Nevertheless, there is clearly a trend of haematological tumours
developing at earlier age (mean age at diagnosis 6 years) than
brain/CNS tumours (mean age at diagnosis 9 years) and
LS-associated tumours (mean age at diagnosis 17 years). The
youngest patient with colon cancer was 8 years at diagnosis,
while the youngest patient with a NHL was only a few months
old, and brain tumours were diagnosed in three patients already
at the age of 2 years.
Figure 1 illustrates the differences in the prevalence of these
three main tumour groups in CMMRD patients with biallelic
MLH1/MHS2 mutations compared with those with MSH6 and
PMS2 biallelic mutations, respectively. Brain tumours were sig-
nificantly more prevalent in PMS2 mutation carriers than in
MLH1/MSH2 biallelics (p=0.01), and there was a trend of them
being more prevalent also in MSH6 than in MLH1/MSH2 bialle-
lics. Haematological malignancies are significantly more preva-
lent in MLH1/MSH2 than PMS2 biallelics (p=0.04). Also,
haematological malignancies were more often the primary
tumour in MLH1/MSH2 mutation carriers comprising 38% of
the cases (vs 25% and 16% of the MSH6 and PMS2 mutation
carriers, respectively). In contrast, 50 and 60% of the PMS2 and
MSH6 mutation carriers, respectively, but only 30% of the
MLH1/MSH2 biallelics developed a brain tumour as first malig-
nancy. No substantial differences for the prevalence of
LS-associated tumours were observed between the groups.
Looking at the mean age at diagnosis of the malignancy,
MLH1/MSH2 biallelics tend to develop each tumour entity at
Table 2 Malignancies in 146 CMMRD patients
Malignancies Number of tumours Median age at diagnosis in years Age range at diagnosis in years
Haematological malignancies
Non-Hodgkin’s lymphoma 31 5 0.4–17
Lymphoid leukaemia 9 6 2–21
Acute myeloid leukaemia 5 9.5 6–17
Malignant lymphoma 1 15
Atypical chronic myeloid leukaemia 1 1
Acute leukaemia 1 2
Total 48 6 0.4–21
Malignant brain and central nervous system tumours
High-grade gliomas 58 9.5 2–40
sPNET 8 8 4–17
Medulloblastoma 7 7 4–12
Infiltrating cerebral angiosarcoma 1 2
Cerebral anaplastic ganglioma 1 9
Papillary ganglioneural tumour 1 11
Not specified brain tumour 5 8 4–24
Total 81 9 2–40
LS-associated carcinomas
Colon/rectum* 59 16 8–48
Duodenum/jejunum/ileum 18 28 11–42
Endometrium 6 28 23–44
Bladder/ureter (papillary transitional cells) 2 20 19 & 21
Ureter/renal pelvis (unspecified) 2 19 15 & 22
Ovaries 1 17
Total 88 17 8–48
Others
Neuroblastoma 1 13
Nephroblastoma (Wilms tumour) 1 4
Ovarian neuroectodermal tumour 1 21
Infantile myofibromatosis 1 1
Rhabdomyosarcoma 1 4
Basal cell carcinoma 1 n.r.
Muco-epidermoid ca. of parotis 1 11
Osteosarcoma 1 24
Total 8
*Multiple synchronous bowel carcinomas were counted as one malignancy.
CMMRD, constitutional mismatch repair deficiency; LS, Lynch syndrome; sPNET, supratentorial primitive neuroectodermal tumours.
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lower age than MSH6 and PMS2 biallelics (figure 1 and see
online supplementary table S2). This trend is also reflected in an
overall lower mean age at diagnosis of the first malignancy in
CMMRD patients with MLH1/MHS2 mutations than in MSH6
and, particularly, PMS2 biallelics (see table 1). However, the
latter numbers are not very different (7.5 years in MLH1/MHS2
biallelic vs 8 and 10 years in MSH6 and PMS2 biallelics, respect-
ively). This may be partly due to the fact that the group of
MLH1/MSH2 biallelics contains two siblings compound hetero-
zygous for the hypomorphic MSH2 mutation c.1A>G and a
deletion encompassing exons 1–6 of this gene (c.1-?_1076+?
del). These patients developed multiple LS-associated tumours
in their fourth and fifth decades of life.19 Excluding these two
siblings, the differences between the genetic groups are more
obvious (5 vs 8 and 10 years). The percentage of biallelic muta-
tion carriers with more than one malignancy was lowest in
MLH1/MSH2 and highest in PMS2 biallelics (see table 1). This
may indicate that the chance to survive the first tumour and
develop a second metachronous malignancy is better in PMS2
biallelic mutation carriers than in MLH1/MSH2 biallelics. This
observation adds to the notion that patients with biallelic
MLH1/MSH2 mutations show overall a more severe phenotype
than those with biallelic MSH6 and PMS2 mutations.
There were also a number of additional malignancies that do
not fall into the three main tumour categories and that were
diagnosed each in so far only one genetically proven CMMRD
patient. These malignancies included embryonal tumours and
sarcomas. Apart from the genetically proven CMMRD patient
listed in table 2, rhabdomyosarcomas were also reported in two
patients with an inferred diagnosis of CMMRD.6 20
Rhabdomyosarcoma, the most common soft tissue sarcoma in
children, is discussed to be associated with NF1.21 Given the
phenotypic overlap of CMMRD with NF1, CMMRD patients
with rhabdomyosarcoma and signs of NF1 may have been mis-
diagnosed in the past. Hence, there is evidence that the fre-
quency of CMMRD among patients with rhabdomyosarcoma
may be higher. Also, there is so far unreported evidence that
osteosarcoma may be a tumour entity that is more frequent in
CMMRD than previously thought (Brugières for the French
CMMRD consortium unreported).
Premalignancies and non-malignant tumours in CMMRD
patients
The spectrum of tumours found in CMMRD patients includes
also premalignancies and non-malignant tumours (see table 3).
A high percentage of the published CMMRD patients devel-
oped adenomas of the gastrointestinal tract, which are consid-
ered the premalignant lesions from which gastrointestinal
cancers develop. Adenomas of the colon and rectum were
reported in 52 (36%) of the patients, and many of them devel-
oped multiple synchronous adenomas ranging from a few to up
to 100 polyps22 reminiscent of (attenuated) FAP.23 24 In eight
patients, adenomas of the small bowel were reported. At least
one patient developed gastric polyps.
Hepatic adenomas were found in three patients with a genet-
ically confirmed diagnosis of CMMRD,25 as well as in one of
the siblings from the original Turcot family10 and in one so far
unreported CMMRD patient. The latter two cases are not
Figure 1 Differences in the
prevalence of the three main tumour
types, that is, haematological, brain
and LS associated, in CMMRD patients
with the three different genotypes,
that is, MLH1 or MSH2 (MLH1/MSH2),
MSH6 and PMS2 biallelic mutations,
are shown. The number of patients
with the respective tumour type within
the genotype group is given above the
representative bar, and the mean age
at tumour diagnosis is given in years
(y) within each of the bars. Statistically
significant differences in the
prevalence of the tumour types
between the genotypes are indicated.
χ2 testing was used for statistical
analysis.
Table 3 Premalignancies and non-malignant tumours in 146 CMMRD patients
Type of neoplasia Number of patients Median age at first diagnosis in years Age range at first diagnosis in years
Adenomas/polyps of colon and rectum 52 14 6–46
Duodenal adenomas/polyps 8 14 10–32
Gastric polyps 1 n.r. n.r.
Hepatic adenomas 3 9 –
Neurofibromas 7 n.r. n.r.
Optic glioma 1 3
Pilomatricomas (epithelioma of Malherbe) 2 2 years 8 months –
Polyps of vocal cord 1 in infancy –
CMMRD, constitutional mismatch repair deficiency; n.r., not reported.
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included in table 3 because the patient reported by Turcot was
never molecularly confirmed and the unreported patient was
found to be homozygous for a so far unknown PMS2 missense
variant and, hence, his molecular diagnosis could not be con-
firmed unambiguously.
Benign cutaneous or plexiform neurofibromas were reported
in eight patients and one patient had an optic glioma.26 The
latter might be a sign of (mosaic) NF1 in this CMMRD patient
who also had six CALMs and freckling and, therefore, met the
diagnostic criteria of NF1. This WHO grade I tumour is not
listed in table 1 as it is not considered a malignant brain
tumour. But it is noteworthy that Ostergaard and colleagues27
report a patient with a brain tumour of the left parieto-occipital
area, which initially showed the histology of a pilocytic astrocy-
toma. This tumour recurred within 6 months, then characterised
as anaplastic astrocytoma.
Pilomatricomas, also termed calcifying epithelioma of
Malherbe, are benign tumours of the hair follicles. In two
patients with genetically confirmed CMMRD syndrome, mul-
tiple pilomatricomas were reported. The authors proposed that
the presence of multiple pilomatricomas that is seen very rarely
in otherwise healthy individuals should raise a suspicion for an
underlying MMR repair defect when observed in a paediatric
cancer patient.28 Of note, there may also be an association of
multiple pilomatricomas with MUTYH-associated polyposis,29 a
polyposis syndrome that has certain phenotypical and patho-
mechanistic overlap with CMMRD since both recessively inher-
ited tumour predisposition syndromes are caused by DNA
repair defects leading to attenuated polyposis although usually
in different age groups.
One patient had polyps of the vocal cord in infancy; the link
of this latter sign with CMMRD is not proven yet.
Non-neoplastic features of CMMRD
The most prevalent non-neoplastic features seen in CMMRD
patients are CALMs and other pigmentary alterations. More
than 60% (91/146) of the CMMRD patients were reported to
show at least one CALM or hyperpigmented skin area (table 4)
and only four published19 30–32 and one so far unpublished
patient have been explicitly reported to lack these pigmentary
alterations. The vast majority of these patients had multiple
(two or more) CALMs, but they did not always reach the critical
number of ≥6, which is needed to be a diagnostic criteria of
NF1. Several authors stress that the degree of pigmentation and
the shape of these hyperpigmented skin macules often differed
from the CALMs typically seen in NF1 patients. Nevertheless,
several patients showed classical NF1-associated CALMs.
Twenty-seven patients showed (often in addition to CALMs)
other features diagnostic for NF1. These features included
freckling in 14, neurofibromas in 8, Lisch nodules in 5 and tibia
pseudarthrosis, sphenoid wing dysplasia and optic glioma each
in 1 patient. Also, 3 of the 27 patients were reported to have a
NF1 phenotype, but the signs were not specified.13 33 Because
several patients showed a segmental/regional distribution of
NF1 signs6 34 and a postzygotic NF1 mutation was found in
one patient,35 it is thought that classical CALMs and other
typical NF1 signs in CMMRD patients result from postzygotic
NF1 mutations present in a segmental or mosaic status. Another
pigmentary abnormality reported in at least nine CMMRD
patients are areas of skin hypopigmentation, also reported as
‘ash leaf spots’ or ‘vitiligo’ (table 4).
An analysis of three patients with biallelic PMS2 and eight
with biallelic MSH6 mutations has shown that constitutional
deficiency of these MMR genes leads to impaired immuno-
globulin (Ig) class switch recombination characterised by a
decrease or absence of IgG2, IgG4 and IgA concomitant (par-
ticularly in young patients) with increased IgM levels, that is,
hyper-IgM syndrome.36 37 IgA deficiency indicative of this
humoral defect was also observed in a patient with a homozy-
gous MSH2 mutation.38 Hence, in total 12 CMMRD patients
were reported to show defects in Ig class switch. In most of the
other CMMRD patients, this parameter was not tested since an
increased susceptibility to severe and persistent infection that
would be indicative of an immune defect was noticed only in
very few CMMRD patients.
Eight CMMRD patients had congenital malformations.
Agenesis of the corpus callosum (ACC) is reported so far in four
patients, and in three of these patients grey matter heterotopia
was also detected.30 39 Baas and colleagues30 render evidence
that these features are seen more frequently in CMMRD than in
the general population. Therefore, it was suggested that ACC
with or without grey matter heterotopia is associated with
CMMRD and should raise the suspicion of this disorder in a
paediatric cancer patient. It was speculated that these isolated
and largely asymptomatic brain malformations in CMMRD
patients result from early embryonic somatic mutations in one
or more of the genes implicated in the callosal development.
Equally, it may be speculated that somatic mutations in develop-
mental genes (presumed to occur more frequently in CMMRD)
could be responsible also for other malformations that were
observed in CMMRD patients. Non-therapy-induced brain
cavernomas were seen in two published patients25 40 and one so
far unreported patient. The combination of congenital asplenia,
left isomerism and a ventricular septum defect was observed in
one patient.23 It will be worthwhile to systematically analyse
whether these and other malformations are also found at a
higher frequency in CMMRD patients than in the general
population.
Furthermore, two patients developed lupus erythematosus31 41
and two haemangioma of the skin.30 42
SUGGESTIONS OF THE EUROPEAN CONSORTIUM ‘CARE
FOR CMMRD’
Diagnostic criteria that should raise the suspicion of
CMMRD syndrome in a cancer patient
An early and definite diagnosis of CMMRD in a paediatric and
young adult cancer patient is desired for several reasons. (1)




Café au lait spots or area of skin hyperpigmentation 91
Café au lait spots and other signs reminiscent of NF1 27
Area of skin hypopigmentation 9
Mild defects in immunoglobulin class switch
recombination: IgG2↓ and/or IgG4↓ and/or IgA↓ and/or
IgM↑
12
Agenesis of the corpus callosum with and without grey
matter heterotopia
4
Cavernous brain haemangioma 3
Capillary haemangioma of skin 2
Combination of congenital malformations (asplenia, left
isomerism, ventricle septum defect)
1
Lupus erythematosus 2
CMMRD, constitutional mismatch repair deficiency.
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Although the true cancer risk of CMMRD is currently not
known (and may be overestimated since we have to rely on a
potentially biased cohort of patients), the available data from
the published patients with this rare disorder suggest that it is
extraordinarily high. CMMRD patients who survive their first
malignancy or in whom a premalignancy has been removed
have a high risk of developing a second often different (pre-)
malignancy. To improve the prognosis, surveillance should be
offered at least for bowel cancer and brain tumours as recently
proposed by the European consortium.43 (2) Early and definite
diagnosis may also be a prerequisite in the future to adjust treat-
ment to the underlying MMR defect and the high risk of a sec-
ondary malignancy. Currently, no information is available
regarding the optimal treatment for CMMRD patients. But
careful attention should be given to a possibly reduced efficacy
and increased cytotoxicity of certain chemotherapeutic agents
due to constitutionally impaired mutation repair.7 44 Since
MMR-deficient cells are profoundly resistant to O6 methylators
such as temozolomide,45 46 the risk of therapy failure may be
increased in CMMRD patients treated with this drug.
Furthermore, these drugs may increase the risk of second
primary tumours by accelerating the rate of unrepaired muta-
tions. (3) Siblings of a CMMRD patient have a 25% risk of
having inherited the same genotype and, hence, equally a high
risk for childhood cancer. (4) The parents of CMMRD patients
and 50% of their siblings as well as other more distantly related
family members are heterozygous for the MMR mutation(s)
and, therefore, have an increased risk for LS-associated tumours
in adulthood. A definite molecular diagnosis is needed to offer
the families of CMMRD patients appropriate counselling and
discuss with them the options of predictive testing as well as
prenatal/preimplantation diagnostics if this is desired.
It might be considered desirable to establish a diagnosis
before the development of the first malignancy in a biallelic
MMR gene mutation carrier. Currently, however, this seems to
be only achievable for siblings of a tumour patient with a
molecularly confirmed diagnosis. The non-neoplastic features of
CMMRD may be too subtle and unspecific to raise the suspi-
cion in a child without a malignancy if there is no family history
of CMMRD or diagnosis of LS in the family. Therefore, it was
decided at the first meeting of the C4CMMRD consortium that,
at the time being, the group will only propose clinical criteria
that should raise the suspicion of CMMRD when present in a
cancer patient. Questions that were discussed among the group
were
A. Which tumour entities should raise a suspicion?
B. What is the age limit for a patient with a specific tumour
entity to be suspected?
C. Which non-neoplastic feature should be considered a diag-
nostic criterion?
Ad A): The spectrum of malignancies in CMMRD is very
broad (see table 2). Therefore, any malignancy in a paediatric
(young adult) patient could be a CMMRD-associated one.
Nevertheless, the index of suspicion should be higher in tumour
entities that are overrepresented in CMMRD patients compared
with their proportion in all tumours of the general population.
Taking this into account, we developed a scoring system for the
suspected diagnosis of CMMRD. Tumours assigned three points
are highly specific for CMMRD syndrome. A diagnosis of
CMMRD should be suspected in patients with these tumour
entities no matter whether they show additional (non-
neoplastic) features of CMMRD or not. Malignancies assigned
two points are overrepresented in CMMRD but less specific.
Additional features or tumours that add up to three points need
to be present in patients with these malignancies to suspect
CMMRD. All other malignancies are assigned one point , and
additional tumours or features strongly pointing into the direc-
tion of CMMRD need to be present to raise a suspicion that
should entail further diagnostic steps.
Colorectal or other cancers of the LS spectrum are extremely
rare below the age of 25 years even in LS and FAP. Because they
are highly suggestive for CMMRD, which phenotypically pre-
sents in several cases as a very early onset form of LS, three
points are assigned to these tumours.
Multiple bowel adenomas are a frequent finding in CMMRD,
which hence shows clinical overlap also with (attenuated) FAP.
Herkert et al23 proposed that in the absence of proven APC or
MUTYH germline mutations, patients with childhood-onset
adenomatous polyposis should be considered for MMR gene
mutation testing, especially when they have features of NF1. In
CMMRD, both the adenoma formation and the adenoma car-
cinoma transition may be accelerated due to the greatly
enhanced mutation rate in neoplastic and non-neoplastic tissue.
In agreement with this notion, most (35/52) of the CMMRD
patients with adenomas showed high-grade dysplasia in at least
one of them or had synchronous bowel cancer. Therefore,
CMMRD syndrome should be considered as a differential diag-
nosis also in a patient under the age of 25 years (for considera-
tions concerning the age limit of 25 years, see ad (B)) with (i)
multiple adenomas if a heterozygous APC mutation or biallelic
MUTYH mutations are absent (exclusion of POLD1 and POLE
hotspot mutations may also be considered47) or (ii) in a patient
with a single adenoma with high-grade dysplasia. Consequently,
multiple bowel adenomas and absence of an APC/MUTYH
Table 5 Indication criteria for CMMRD testing in cancer patients
Indication for CMMRD testing in a cancer patient
≥3
points
Malignancies/premalignancies: one is mandatory; if more than one is
present in the patient, add the points
Carcinoma from the LS spectrum* at age <25 years 3 points
Multiple bowel adenomas at age <25 years and absence of APC/
MUTYH mutation(s) or a single high-grade dysplasia adenoma at
age <25 years
3 points
WHO grade III or IV glioma at age <25 years 2 points
NHL of T-cell lineage or sPNET at age <18 years 2 points
Any malignancy at age <18 years 1 point
Additional features: optional; if more than one of the following is present,
add the points
Clinical sign of NF1 and/or ≥2 hyperpigmented and/or
hypopigmented skin alterations Ø>1 cm in the patient
2 points
Diagnosis of LS in a first-degree or second-degree relative 2 points
Carcinoma from LS spectrum* before the age of 60 in first-degree,
second-degree, and third-degree relative
1 point
A sibling with carcinoma from the LS spectrum*, high-grade glioma,
sPNET or NHL
2 points
A sibling with any type of childhood malignancy 1 point
Multiple pilomatricomas in the patient 2 points
One pilomatricoma in the patient 1 point
Agenesis of the corpus callosum or non-therapy-induced cavernoma
in the patient
1 point
Consanguineous parents 1 point
Deficiency/reduced levels of IgG2/4 and/or IgA 1 point
*Colorectal, endometrial, small bowel, ureter, renal pelvis, biliary tract, stomach,
bladder carcinoma.
CMMRD, constitutional mismatch repair deficiency; LS, Lynch syndrome; NHL,
non-Hodgkin’s lymphomas; sPNET, supratentorial primitive neuroectodermal tumours.
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mutation and/or one adenoma with high-grade dysplasia under
the age of 25 have a score of three points.
High-grade gliomas, including glioblastoma, gliosarcoma, ana-
plastic astrocytoma, oligodendroglioma and others, are rare
tumours in childhood and adolescence. According to the data of
the French Brain Tumour Data Bank48 and the German child-
hood cancer register (http://www.kinderkrebsregister.de), they
represent 15% of all brain/CNS tumours in childhood and ado-
lescence. Hence, assuming that a quarter of all tumours in child-
hood are brain/CNS tumours, high-grade gliomas represent less
than 5% of all tumours in childhood/adolescence. In contrast,
26% of all malignancies so far seen in CMMRD patients are
high-grade gliomas. Equally, CNS-PNET constituting 3.5% of all
so far reported malignancies in CMMRD (vs 0.5% of all child-
hood tumours in the general population) are overrepresented in
CMMRD. Among the haematological tumours, NHL are over-
represented in CMMRD. NHL constitute ∼5–7% of all child-
hood tumours but 14% of all CMMRD-associated
malignancies. Of note, at least 65% (20/31) of the
CMMRD-associated NHL were from the T-cell lineage and at
least 42% (13/31) were T-cell lymphoblastic lymphomas. This is
in contrast to the distribution in the general population where
∼65% are from the B-cell lineage and more than 50% are
mature B-NHL.49 Hence, NHL of the T-cell lineage mainly
account for the overrepresentation of NHL in CMMRD. Taken
together, T-NHL, high-grade gliomas and CNS-PNET are con-
sidered malignancies typical for CMMRD and are assigned two
points in the scoring system.
Ad B): The age at diagnosis of the first malignancy ranges
from 0.4 to 39 years in CMMRD patients (table 1). However,
the vast majority, that is, 120 of the 146 CMMRD patients,
were younger than 18 years of age when their first tumour was
diagnosed. Only 17 patients were between 18 and 25 years
when they developed their first tumour, which was a CRC in 11
patients, a glioblastoma in 1 patient and an oligodendroglioma
in 1 patients. The remaining four patients had colorectal aden-
omas when they were young adults. Only four patients were
older than 25 years when they were diagnosed with their first
tumour; in all four cases a CRC.13 19 41 These four patients
carried at least one allele a likely hypomorphic MSH2, MSH6
and PMS2 mutation, respectively, and, therefore, may genetically
as well as clinically represent an intermediate phenotype
between CMMRD and LS. Based on the observations in the
patients reported so far, we set the age limit at diagnosis of the
first tumour at 25 years for patients with CRC, colorectal aden-
omas and malignant gliomas. For all other patients with malig-
nancies, the age limit is <18 years (see table 5).
Ad C): Non-neoplastic features are weighted according to
their specificity for CMMRD and their frequency in the general
population with one point or two points.
Presence of (segmental) NF1 signs, primarily multiple (≥6)
CALMs and freckling, is so far the most commonly reported
non-neoplastic feature associated with CMMRD, and it has
been stressed already in several reports that presence of one or
more of these signs should raise the suspicion of CMMRD in
any paediatric cancer patient with the exception of children/
young adults with clearly NF1-associated malignancies, such as
a peripheral nerve sheath tumour (MPNST) or a juvenile myelo-
monocytic leukaemia ( JMML) or with a parent who is also
diagnosed with NF1. Hence, this highly specific feature is
weighted two points.
Although many CMMRD patients came to attention through
the presence of NF1 signs, our analysis of the reported cases
clearly indicates that limiting suspicion to patients showing
classical NF1 signs will miss a number of patients. In several
CMMRD patients, the number of CALMs has been reported to
be below six, which is the necessary number to be diagnostic for
NF1. Furthermore, several CMMRD patients do not show clas-
sical NF1-associated CALMs but have different kinds of skin
hyperpigmentation and hypopigmentation. As an isolated
finding these alterations are frequent in the general population.
A study assessing the frequency of CALMs among school chil-
dren aged 4–11 years showed that ∼20% (146/732) had one
CALM. However, only 4.1% (30/732) and 1.2% (9/732) had
two and three CALMs, respectively.50 Merks and colleagues51
report a slightly lower frequency of solitary and multiple CALM
in 13% and 3.3% of school children, respectively. Hence, the
likelihood of having a childhood malignancy and two or more
CALMs (hyperpigmented macules) by pure chance is very low.
The same is likely the case for hypopigmented macules.
Therefore, the presence of two or more skin areas of hyperpig-
mentation or hypopigmentation with a minimum diameter of
1 cm should be another feature that should raise the suspicion
of CMMRD. This feature is also weighted two points.
Brain malformations such as agenesis of corpus callosum and
non-therapy-induced cavernoma as well as pilomatricomas/
epitheliomas of the Malherbe are rare in the general population.
But they seem to have a higher incidence in CMMRD patients
(see sections ‘Premalignancies and non-malignant tumours in
CMMRD patients’ and ‘Non-neoplastic features of CMMRD’).
Therefore, these features should also raise the suspicion of
CMMRD when present in a childhood cancer patient and are,
thus, weighted depending on their frequency in the general
population 1–2 points. The frequency of brain malformations in
CMMRD patients still needs to be evaluated prospectively. As
long as they have not been shown to be more frequent, we do
not advocate performing cranial MRI unless required for other
clinical reasons to test for these features only in order to
confirm the diagnosis CMMRD in a cancer patient. The brain
malformations add one point to the score of a cancer patient.
Multiple pilomatricomas, which are extremely rare and always
indicate an underlying genetic defect, add two points. A single
pilomatricoma adds only one point.
Consanguinity of the parents and/or homozygosity for one
(founder) mutation is observed in 46 of the 91 so far reported
families with CMMRD patients. However, consanguineous mar-
riages are common in several ethnic and religious groups of the
European population. Therefore, we decided that consanguinity
should add one point and raise the suspicion of CMMRD in a
patient with a paediatric cancer that is overrepresented in
CMMRD syndrome and in any other paediatric cancer patient
who has one of the other features.
Due to the impaired class switch recombination, reduced
IgG2/4 and/or IgA levels could be observed in several CMMRD
patients. But this feature is neither very specific for CMMRD
nor particularly rare in the general population. Hence, it is also
assigned one point.
Other criteria for suspecting CMMRD in a child with a
malignancy are (i) a sibling with a malignancy and (ii) the
molecular diagnosis of LS or an LS-associated tumour before
the age of 60 years in a first-degree , second-degree or third-
degree relative of the patient. When assigning points to these
criteria, it was taken into consideration that typical CMMRD
tumours in a sibling should raise a higher index of suspicion
(two points) than any other tumour in a sibling (one point).
Equally, a definite diagnosis of LS in the family is assigned two
points, whereas an LS-associated tumour before the age of
60 years in a first-degree, second-degree or third-degree relative
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of the patient is scored only one point. A LS-associated tumour
in a relative that has been shown to be microsatellite stable, and
hence, is very likely a sporadic tumour should not be taken into
account.
According to the three-point scoring system summarised in
table 5, CMMRD syndrome should be suspected in an individ-
ual who reaches a score of minimum three points. The points
should be counted by adding the points assigned to the malig-
nancy/malignancies and those assigned to additional features.
When using this system, it has to be kept in mind that several of
these features listed in table 5 may be present also in a patient
with a different (childhood) cancer predisposition syndrome,
like Fanconi anaemia, ataxia telangiectasia, Bloom syndrome,
Peutz–Jeghers syndrome, tuberous sclerosis and others. These
syndromes are usually associated with characteristic anomalies
that are not listed in table 5. Therefore, patients with signs spe-
cific for another cancer predisposition syndrome except for NF1
should first be tested for the other cancer predisposition syn-
drome. Patients who have clearly NF1-associated malignancies
such as JMML or MPNST and signs reminiscent of NF1 should
be first tested for a NF1 mutation. There is also an overlap of
CMMRD with Li Fraumeni syndrome (LFS). The tumour spec-
trum of the latter encompasses brain tumours and, to a lesser
extent, haematological neoplasms. In families fulfilling
Chompret’s criteria,52 a TP53 germline mutation should be
ruled out first.
Diagnostic steps to substantiate the diagnosis CMMRD
Patients reaching a score of three points should be further ana-
lysed to confirm or refute the suspected diagnosis of CMMRD
syndrome. The diagnostic steps in these patients largely follow
the protocols developed for LS, which involves analysis of
microsatellite instability (MSI) and/or immunohistochemical
(IHC) staining of the four MMR proteins.
IHC analysis to assess the expression loss of the affected
MMR protein can be effectively employed in all solid tumours
of CMMRD patients and has the advantage to guide subsequent
mutation analysis in the four MMR genes. In general, biallelic
truncating mutations in PMS2 or MSH6 will result in isolated
loss of these proteins, whereas mutations in MLH1 or MSH2
will lead to concurrent loss of MLH1/PMS2 or MSH2/MSH6,
respectively, since MLH1 and MSH2 are the obligatory partners
in the formation of MLH1/PMS2 and MSH2/MSH6 heterodi-
mers. Of note, in the case of an underlying missense mutation,
IHC may show normal expression of the affected MMR gene,
which may be a possible pitfall when using IHC analysis to
confirm suspected CMMRD. In contrast to LS where expression
loss is observed only in neoplastic cells, in CMMRD patients
IHC detects expression loss of one (or two) of the MMR pro-
teins in both neoplastic and non-neoplastic tissues. Hence, nega-
tive IHC staining in neoplastic and surrounding normal cells
should not be interpreted as a failure of proper staining and
care should be taken to use a (on slide) staining control from a
different individual. In principle, expression loss of one of the
MMR genes can also be demonstrated in blood lymphocytes of
CMMRD patients, as shown by western blotting37 but possibly
also by IHC staining on cytospin preparations.
MSI tests for small misalignments, that is, insertion–deletion
loops (IDL), which arise during DNA replication and remain
uncorrected in the absence of a functional MMR system. It
takes advantage of the fact that repeated-sequence motifs con-
sisting of units of one, two or a few more nucleotides, that is,
microsatellites, are frequent targets of IDL errors that result in
shortening or lengthening of these sequence motifs, a
phenomenon termed MSI. In tissues derived from clonally pro-
liferating MMR-deficient cells, that is, neoplastic cells, MSI is
easily detected by PCR amplification and fragment analysis of a
set of microsatellite markers.53 MSI analysis following the
current protocols for LS uses a panel of 5–6 dinucleotide54 and/
or mononucleotide55 repeat markers. This approach is a reliable
tool to diagnose MMR deficiency in gastrointestinal and other
LS-associated tumours of CMMRD patients. However, standard
MSI analysis as applied in LS frequently fails to show MSI in
brain tumours42 56 57 and other malignancies.30 Currently, the
reasons for this observation are unknown, but it has been
shown that more subtle shifts (shortening or lengthening) of
microsatellite alleles can be observed also in brain tumours and
may be indicative of CMMRD.58 Furthermore, it might be
worth testing whether a different panel of microsatellite
markers would be more sensitive in brain and other tumours of
CMMRD patients.
In principle, MSI can be observed also in DNA from normal,
that is, non-neoplastic, cells of CMMRD patients. However,
because altered microsatellite alleles are present only in a small
proportion of the cells from normal tissue, so far most
approaches used technically demanding single-molecule analyses
(eg, small-pool PCR) to show MSI in normal tissue, that is,
germline MSI (gMSI).59 Recently, a much more simple method
to detect gMSI was presented.60 This assay relies on the analysis
of ‘stutter’ peaks typically associated with microsatellite PCR
products. When quantified by a novel publicly available software
application, the relative peak height of the ‘stutter’ peaks of
selected dinucleotide microsatellites significantly increases in
DNA of CMMRD patients compared with normal controls as
has been confirmed also in a larger cohort of samples (Bodo
et al., in preparation). The main limitation of this assay is that
the relative peak height is not altered in patients with CMMRD
due to biallelic MSH6 mutations. Nevertheless, if this assay
shows in a larger cohort of samples that it is a reliable, simple
and rapid tool to detect CMMRD at least in patients with
PMS2, MLH1 or MSH2 mutations, it would be a good screening
tool and an alternative to IHC in cases where appropriate tissue
is not available.
Taken together, both IHC staining of the MMR genes and
MSI analysis are diagnostic methods to substantiate the sus-
pected diagnosis. Since IHC will also guide target-gene mutation
analysis and has been shown to render reliable results in most
solid tumours, it is considered the preferred method. But as out-
lined, both methods have potential pitfalls and may fail to
confirm the suspected diagnosis. Therefore, we recommend
combining both assays if needed. The final confirmation of the
diagnosis CMMRD should come from the determination of the
causative biallelic mutations in the patient.
Counselling and genetic testing
According to the recommendations of national and international
human genetic societies and the legislation of most European
countries, genetic counselling must be offered to the patients
and/or their parents prior to performing mutation analysis in
the affected child. Patients and/or their parents should be
informed by a team of paediatric oncologists and medical
geneticists about the suspected diagnosis if this is substantiated
by MSI and/or IHC analysis. Considering the burden of this
syndrome, psychological support should systematically be pro-
posed to families. The family has to be informed of potential
therapeutic implications of the test result and also of the high
risk for a second malignancy in a patient with a positive test
result. Genetic counselling must also include information on the
362 Wimmer K, et al. J Med Genet 2014;51:355–365. doi:10.1136/jmedgenet-2014-102284
Cancer genetics








enet: first published as 10.1136/jm





potential 25% recurrence risk in a sibling and on the risks for
LS-associated cancer in possible heterozygous mutation carriers,
particularly both parents.
With the informed consent of the patient and/or the parents,
mutation analysis will be initiated. Reliable and robust compre-
hensive analysis exists for all four MMR genes now including
the historically difficult PMS2 gene. However, when analysing
PMS2, which is the affected gene in more than 50% of
CMMRD patients, special care has to be taken to avoid pitfalls
that arise from high prevalence of hybrid alleles that result from
sequence exchange of the functional gene with its pseudogene
PMS2CL.33 61–66
Preferentially, targeted gene mutation analysis is performed.
However, in cases where tumour tissue is not available for IHC
analysis or the results are inconclusive, mutation analysis of all
four MMR genes can be considered. It is expected that with the
implementation of next-generation sequencing techniques this
may be possible at reasonable costs in many laboratories in the
near future.
CONCLUDING REMARKS
The earlier presented diagnostic criteria to suspect the diagnosis
of CMMRD in a paediatric/young adult cancer patient are
based on the findings of 146 patients. They are developed so
that nearly all of these patients have ≥3 points according to the
scoring system presented in table 5. The only exception are four
patients who developed colon carcinomas as first malignancy at
an age >25 years and who were earlier discussed to have a
genotype and phenotype that represents an intermediate
between LS and CMMRD (see ‘Diagnostic criteria that should
raise the suspicion of CMMRD syndrome in a cancer patient’
ad (B)). Indication of CMMRD in such patients will come from
IHC analysis of tumour tissue that will show loss of the affected
protein not only in neoplastic but also normal mucosa cells. We
tested the criteria also in an independent cohort of 23 patients
of the French cohort who are to the largest part unreported.
For all these patients, we obtained 9–13 points suggesting that
the scoring system is highly sensitive. However, selection bias
has to be kept in mind also for this cohort since also most of
these patients were not selected using the proposed criteria but
were identified because they had multiple malignancies and/or
siblings with malignancies and/or colorectal carcinoma at an
exceptionally young age. Hence, prospective studies are needed
to evaluate the specificity as well as the sensitivity of the pre-
sented criteria.
Nevertheless, it is reasonable to expect that application of the
suggested clinical criteria for CMMRD diagnosis will increase
the number of patients being identified at the time when they
develop their first tumour. This will allow to adjust treatment
modalities and to offer surveillance strategies for (second) malig-
nancies not only to the patient but also to siblings who carry
also a biallelic MMR gene mutation. Still many of these patients
will die from cancer. But a systematic collection and evaluation
of all clinical data will help to improve the management in
CMMRD. Therefore, patients, their siblings and parents should
be asked to be included in an EU registry that will be established
by the C4CMMRD consortium. Data analysis of these patients
and also their siblings and parents will allow determining the
true cancer risk and tumour spectrum of CMMRD.
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